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We analyzed surveillance data on group B streptococcus
(GBS) infection in Finland from 1995 to 2000 and reviewed
neonatal cases of early-onset GBS infection in selected hospi-
tals in 1999 to 2000. From 1995 to 2000, 853 cases were report-
ed (annual incidence 2.2–3.0/100,000 population). We found
32–38 neonatal cases of early-onset GBS disease per year
(annual incidence 0.6–0.7/1,000 live births). In five hospitals,
35% of 26 neonatal cases of early-onset GBS infection had at
least one risk factor: prolonged rupture of membranes, preterm
delivery, or intrapartum fever. Five of eight mothers screened for
GBS were colonized. In one case, disease developed despite
intrapartum chemoprophylaxis. Although the incidence of early-
onset GBS disease in Finland is relatively low, some geograph-
ic variation exists, and current prevention practices are subopti-
mal. Establishing national guidelines to prevent perinatal GBS is
likely to reduce the incidence of the disease. 
G
roup B streptococcus (GBS), a leading cause of invasive
bacterial infections in newborns, also affects pregnant
women and elderly persons (1–4). In the United States, several
studies have reported the incidence of GBS infection in differ-
ent demographic groups, and guidelines were developed and
implemented for the prevention of neonatal infection in the
1990s (1–6). In European countries, however, few population-
based data on GBS infection are available and no national
guidelines have been published (7–10).
In the United States, the recommended strategies to prevent
perinatal GBS disease include either a risk-based or screening-
based approach (5). In the risk-based approach, women in labor
who have risk factors for GBS transmission (e.g., fever, pro-
longed rupture of the membranes, or preterm delivery) are
offered intrapartum chemoprophylaxis. In the screening-based
approach, vaginal and rectal combined swabs are cultured from
all pregnant women and tested for GBS carriage during 35 to
37 weeks’ gestation. Those identified as GBS carriers are
offered intrapartum chemoprophylaxis.
In Finland, laboratory-based surveillance for invasive bac-
terial infections, including GBS, began in 1995. To identify
opportunities for prevention, we analyzed national GBS sur-
veillance data from 1995 to 2000. To assess the proportion of
cases that might have been prevented by using the risk-based or
screening approaches, we reviewed birth histories of infants
with early-onset GBS disease in five hospitals participating in
a nosocomial infection surveillance network from 1999 to
2000. We also conducted two national surveys: one evaluating
the microbiologic methods used to screen for GBS cultures in
Finnish clinical microbiology laboratories and the other on cur-
rent practices related to GBS screening and antibiotic use in
Finnish hospitals with obstetric services.
Methods
Surveillance
Finnish clinical microbiology laboratories routinely notify
the National Infectious Disease Registry of bacterial isolations
from blood and cerebrospinal fluid. Each report includes the
following information: isolation date, birth date, sex, specimen
type, and treatment location. Multiple reports of the same case
are combined in the database if they are received within 3
months of first isolation. A case is defined as isolation of GBS
from blood or cerebrospinal fluid; early-onset neonatal disease
is defined as that occurring in infants <7 days old and late-onset
disease as that occurring in infants 7–89 days old. 
Additional Data Collection and Chart Review
Neonatal GBS cases that occurred in five hospitals from
1999 to 2000 were identified through hospital wide surveil-
lance of nosocomial bloodstream infections in connection with
the Finnish Hospital Infection Program (SIRO). We obtained
data on deliveries, local guidelines for perinatal GBS preven-
tion, and microbiologic data (e.g., screening method, number
of specimens examined, and number of GBS-positive speci-
mens). In cases of early-onset disease, the following data were
abstracted from the medical records: prenatal GBS screening,
intrapartum fever >38°C, prolonged rupture of membranes >18
h before delivery, preterm delivery at <37 weeks of gestation,
receipt of intrapartum antibiotics, and outcome of illness.
Calculation of Incidence Rates and Statistical Analysis
Data from the National Population Registry, including live
births, from 1995 to 2000 were used as denominators to calcu-
late age- and sex-specific incidence rates and early-onset and
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dences during the surveillance period were calculated by using
the total number of cases, population, and live births from 1995
to 2000. To evaluate trends, rates of GBS disease in different
age and sex groups were calculated for each 6-month period
from January 1995 to December 2000. Data were analyzed by
using Epi Info software, version 6.04 (Centers for Disease
Control and Prevention, Atlanta, GA) and SAS software, ver-
sion 8.2 (SAS Institute, Inc., Cary, NC). A Poisson regression
model was used to assess whether the observed changes in the
rates were statistically significant. 
Surveys
In February 2002, we sent structured questionnaires by
electronic mail to 20 of the 28 Finnish clinical microbiology
laboratories and by regular mail to all Finnish hospitals with
obstetric services (n=38). The laboratories were asked about
their methods for screening cultures for GBS and the hospitals
about their GBS prevention policies. 
Results
From 1995 to 2000, a total of 853 cases of invasive GBS
disease were identified. Of bacterial isolates, 96% were
obtained from blood and 4% from cerebrospinal fluid. The
average annual incidence was 2.8 cases per 100,000 population
(range by year, 2.2–3.0) and varied from 1.8 to 4.0 by health
district. In women aged >65 years of age, the incidence
increased significantly, from 1.1 per 100,000 in 1995 to 8.2 per
100,000 in 2000 (p<0.01 by Poisson regression). No trends
were identified in other age or sex groups. 
Infants of <1 year of age had the highest rate and account-
ed for 272 (32%) of 853 of all GBS infections (Table 1); 211
(78%) of 272 were early-onset disease and 203 (96%) of 211
were identified during the first 2 days of life. The average
annual incidence of early-onset infections was 0.6 per 1,000
live births (range by year, 0.6–0.7; 32–38 cases/y; Table 2) and
varied from 0.1 to 1.3 by health district. In 7 of 20 health dis-
tricts in the country, the average annual incidence was >0.7 per
1,000 live births. Among 211 early-onset cases, 98% of isolates
were obtained from blood and 2% from cerebrospinal fluid.
The average annualized incidence of late-onset infections was
0.2 per 1,000 live births (range by year, 0.1–0.3; 6–16 cases/y;
Table 2) and varied from 0.0 to 0.4 by health district. Among
56 cases of late-onset GBS disease, 59% of isolates were
obtained from blood and 41% from cerebrospinal fluid.
From 1999 to 2000, a total of 38,687 women delivered
babies in the five study hospitals, accounting for one third of all
live births in Finland. Of the deliveries, 20% were cesarean
sections and 7% preterm deliveries. None of the hospitals had
a policy for universal maternal screening of GBS. Their proto-
col included screening risk groups only and prescribing intra-
partum prophylaxis for GBS-positive women. Patients who had
previously delivered infants with GBS disease and who had
tested positive for GBS bacteriuria during pregnancy were also
screened. Two hospitals prescribed ampicillin, and three hospi-
tals prescribed penicillin. To identify GBS carriers, four hospi-
tals cultured the samples and one used an antigen test. Only
vaginal swabs were collected. A total of 9,220 screening speci-
mens were obtained; 12% of them were positive for GBS. The
proportion of positive specimens varied from 4% to 21% in the
five hospitals. 
In the study hospitals, 26 cases of early-onset disease
(0.7/1,000 live births) and four cases of late-onset disease
(0.1/1,000 live births) were identified. One premature neonate
died. Delivery occurred at 25 weeks of gestation, and the
screening result was negative. Of 26 women who had infants
with early-onset disease, 1 received intrapartum antibiotics
because of prolonged rupture of the membranes and a positive
screening result. Of the 25 women who did not receive intra-
partum antibiotics, 18 (72%) were not screened. Eight (32%)
developed at least one risk factor (six had duration of ruptured
membranes >18 hours, two had delivery at <37 weeks of ges-
tation, and one had intrapartum fever). Of the 18 women not
screened, 4 (22%) showed risk factors at the time of labor (3
had duration of ruptured membranes >18 hours, and 1 had
delivery at <37 weeks of gestation). 
All 26 isolates from case of early-onset infection and 4 from
cases of late-onset infection were evaluated for antibiotic sus-
ceptibility. All isolates were susceptible to penicillin; two iso-
lates (8%) were resistant/intermediate to erythromycin, and one
isolate (4%) was resistant to clindamycin. 
Surveys
All 20 microbiology laboratories responded. Of the labora-
tories, 13 (65%) had a specific laboratory request for GBS cul-
ture; 9 laboratories requested cultures from vagina (69%) and 8
(62%) from cervix. None of the laboratories recommended rec-
tal cultures. One laboratory used selective broth media to cul-
ture GBS. 
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Table 1. Incidence of invasive group B streptococcus infection by age and sex, Finland, 1995–2000 
Men  Women  Total 
Age group (y)  No. of cases  Rate
a  No. of cases  Rate
a  No. of cases  Rate
a 
<1  143  79.3  129  74.7  272  77.1 
1–14   1  0.04  5  0.2  6  0.1 
15–64   128  1.2  193  1.9  321  1.6 
>64  103  6.0  151  5.4  254  5.6 
All  375  2.5  478  3.0  853  2.8 
aAverage annual incidence (cases per 100,000 population). All directors of the 38 hospitals with obstetric services
responded. Written GBS prevention protocols existed in 30
(79%) hospitals. Most used a combination of risk-based and
screening-based strategies; one routinely screened all pregnant
women for prenatal GBS carriage. Recommendations for
obstetric risk groups include screening patients for GBS when
they have one of the following: premature delivery (87%), rup-
ture of membranes without labor (82%), previous delivery of
an infant with invasive GBS disease (79%), GBS bacteriuria
(66%), and maternal fever during labor (53%). GBS specimens
were usually obtained from the vagina (82%) or cervix (45%).
No rectal cultures were taken. Culture was used to detect GBS
in 82% of laboratories and antigen test in 34%. In 61% of the
hospitals, chemoprophylaxis was given to all identified GBS
carriers; the remaining 39% of hospitals required the presence
of at least one additional obstetric risk factor before prescribing
chemoprophylaxis (Table 3). When screening cultures were not
performed or the results were not available at labor, chemopro-
phylaxis was most often given to risk groups with the follow-
ing obstetric risks: intrapartum fever, previous delivery of an
infant with invasive GBS disease, or prolonged rupture of
membranes. Intrapartum chemoprophylaxis was given par-
enterally in 87% of hospitals and orally in 11%. Penicillin was
recommended in 69%, cephalosporins in 19%, and aminopeni-
cillins in 11% of hospitals. 
Discussion
Compared with rates previously reported from European
countries, the incidence of early-onset GBS disease in Finland
is relatively low (7–14). However, the incidence is twice as
high as rates reported among white infants in the United States
(6). Data from the study hospitals in Finland also indicate that
most mothers of infants with early-onset disease did not receive
intrapartum antibiotics.
In Europe, most studies documenting the occurrence of
early-onset GBS disease during the past decade involved a sin-
gle hospital (10,12–14). European population-based data from
Norway in 2001 showed an incidence of 1 case per 1,000 live
births (8). During the period of our surveillance, the incidence
of early-onset and late-onset infection in Finland remained
unchanged and comparable to rates in a previous nationwide
study conducted from 1985 to 1994 (early-onset disease
0.62/1,000 live births; late-onset disease 0.13/1,000 live births)
(15). The annual number of cases of early-onset disease
appears low, but surveillance is limited to culture-confirmed
cases of invasive disease. The number of newborns in whom
GBS is treated empirically may therefore be larger. 
We also identified considerable variation in rates of early-
onset infection by health district. In Finland, the need for effec-
tive preventive measures was already emphasized during the
1980s, when GBS was identified as the most important etiolog-
ic agent of neonatal septicemia (16). The efficacy of intrapartum
chemoprophylaxis has also been demonstrated by a Finnish
study (17). However, the prophylaxis was only introduced to
heavily colonized patients detected by the streptolatex test.
In our review of 26 cases of early-onset GBS disease, 1
case-patient received intrapartum antibiotics; 31% were
screened prenatally for GBS, and 35% had a risk factor evident
at the time of labor. Most case-patients were not screened and
had no risk factors at the time of labor; of those not screened,
four later developed a risk factor. Screening was performed for
those in risk groups; some patients, such as those who had pre-
viously delivered infants with GBS disease or who tested pos-
itive for GBS bacteriuria during pregnancy, were unnecessarily
screened. In addition, the site where cultures were taken and
isolation method used differed from those recommended
(5,18–22).
In the United States, the decline in the incidence of GBS
disease in newborns coincided with the implementation of con-
sensus guidelines for the prevention of perinatal GBS disease
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Table 2. Annual incidence of early-onset and late-onset invasive group B streptococcus infections, Finland, 1995–2000 
   1995  1996  1997  1998  1999  2000 
Early-onset disease             
No. of cases  37  37  34  38  33  32 
Incidence
a  0.6  0.6  0.6  0.7  0.6  0.6 
Late-onset disease             
No. of cases  8  16  6  10  9  7 
Incidence
a  0.1  0.3  0.1  0.2  0.2  0.1 
aCases per 1,000 live births. 
Table 3. High risk groups for whom intrapartum antibiotic prophylaxis is recommended in 38 Finnish hospitals with obstetric services, 2002
a 
No. of hospitals (%) 
Risk group  GBS specimen taken (result positive)
b  GBS specimen not taken (results unknown) 
GBS-positive mothers  23 (61)  – 
GBS bacteriuria during current pregnancy  15 (39)  15 (39) 
Invasive GBS disease in previously delivered child  25 (66)  25 (66) 
Delivery <37 wk gestation  18 (47)  9 (24) 
Rupture of membranes >18 h  26 (68)  19 (50) 
Intrapartum fever >38°C  31 (82)  33 (87) 
aGBS, group B streptococcus. 
bOnly one hospital routinely screened all pregnant women for prenatal GBS carriage. 472 Emerging Infectious Diseases • Vol. 9, No. 4, April 2003
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beginning in 1996 (1). From 1993 to1998, the incidence of
GBS declined 65% from 1.7 to 0.6 per 1,000 live births. Data
from 1998 to 1999 indicate a further decline in incidence in
selected surveillance areas. Among certain demographic
groups, such as white infants, the rate has declined to 0.3 per
1,000 live births (6). A recent review of >300 cases of early-
onset infection from the United States also showed missed
opportunities for prevention, including cases that would not
have been prevented even with perfect implementation of pro-
phylaxis strategies: 21% of cases occurred despite administra-
tion of intrapartum antibiotics, 35% of case-patients had been
screened perinatally for GBS, and 44% had a risk factor evident
at the time labor (2,6). Of case-patients not screened for GBS,
40% showed none of the risk-based criteria for prophylaxis.
GBS infection in adults in Finland accounted for 67% of the
total cases. The average annualized incidence of invasive GBS
infection in adults varied from 1.6 to 5.6 per 100,000 popula-
tion by age group. Although the incidence among elderly
women was slightly lower than in elderly men, this number
appears to be increasing. This finding is similar to previous
population-based incidence data reported in 1989 to 1990 from
metropolitan Atlanta, Georgia, where 48% of the total GBS
cases were in adults; the annual incidence was 6.2 per 100,000
(3). Because the Atlanta study focused on nonpregnant adults
and our study did not have information on the pregnancy status
of the patients, age-specific rates cannot be compared. Recent
U.S. data that included pregnant and nonpregnant adults indi-
cate a marked increase in rates among adults, particularly in
elderly persons and those with underlying illness, and vary
between 2.1 to 21.9 per 100,000 by age group (4). The reasons
for differences in rates of GBS disease between countries may
include demographic differences, socioeconomic factors, and
variations in clinical practices, such as the frequency of taking
blood cultures in diagnostic examinations. Another suggested
independent risk factor for both early-onset and late-onset GBS
infection in neonates is being of black race (3,4). However, the
association may also be linked to socioeconomic factors. The
increasing prevalence of diabetes mellitus and other underlying
conditions may contribute to the increasing rates of GBS infec-
tion in adults. 
Acommon concern in the risk-based prevention approach is
that a large number of women would receive unnecessary
antibiotics. Widespread use of antibiotics can lead to an
increase in allergic reactions, emergence of resistant strains,
and cases of antibiotic colitis. The use of intrapartum antibi-
otics in the United States has doubled from 1996 to 1999, coin-
ciding with GBS prevention implementation (23). We were
unable to obtain information on how widely prophylaxis is cur-
rently used in Finland because data on type, dose, and time of
administration of intrapartum antibiotics are not documented in
hospital databases. Unnecessary antibiotic use could be
reduced by not offering GBS prophylaxis to women who are
not carriers. A recent study suggested that screening may be
more effective in prevention than the risk-based approach (23).
Screening reaches a broader population, and persons who are
screened are more likely to receive prophylactic antibiotics.
However, wide-scale screening for GBS colonization may be
difficult to implement.
The results of our study should be used to develop and
implement national guidelines for prevention of perinatal GBS.
Such guidelines would standardize prevention practices, ration-
alize the use of intrapartum antibiotics, and reduce the inci-
dence of perinatal GBS disease. Further studies should be done
to investigate the reasons for incidence increase among elderly
women.
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